NasdaqGS - Delayed Quote USD
10x Genomics, Inc. (TXG)
At close: October 17 at 4:00 PM EDT
After hours: October 17 at 7:55 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 18 | 18 |
| Avg. Estimate | -0.34 | -0.23 | -1.38 | -1 |
| Low Estimate | -0.57 | -0.36 | -1.68 | -1.59 |
| High Estimate | -0.27 | -0.12 | -1.21 | -0.52 |
| Year Ago EPS | -0.79 | -0.41 | -2.18 | -1.38 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 18 | 18 |
| Avg. Estimate | 158.63M | 183.11M | 636.59M | 700.23M |
| Low Estimate | 151.6M | 156.79M | 602.54M | 652.02M |
| High Estimate | 163.2M | 194.6M | 651.9M | 762.8M |
| Year Ago Sales | 151.26M | 183.98M | 618.73M | 636.59M |
| Sales Growth (year/est) | 4.90% | -0.50% | 2.90% | 10.00% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.46 | -0.36 | -0.5 | -0.48 |
| EPS Actual | -0.79 | -0.41 | -0.5 | -0.32 |
| Difference | -0.33 | -0.05 | 0 | 0.16 |
| Surprise % | -71.70% | -13.90% | 0.00% | 33.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.34 | -0.23 | -1.38 | -1 |
| 7 Days Ago | -0.34 | -0.21 | -1.37 | -0.98 |
| 30 Days Ago | -0.33 | -0.19 | -1.35 | -0.94 |
| 60 Days Ago | -0.34 | -0.2 | -1.35 | -0.95 |
| 90 Days Ago | -0.37 | -0.23 | -1.59 | -1.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | -- | -- |
| Up Last 30 Days | 3 | 3 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 2 | 3 | 3 |
Growth Estimates
| CURRENCY IN USD | TXG | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 57.00% | -- | -- | 4.10% |
| Next Qtr. | 43.90% | -- | -- | 7.60% |
| Current Year | 36.70% | -- | -- | 2.50% |
| Next Year | 27.50% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 51.40% | -- | -- | 11.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 10/15/2024 |
| Reiterates | Stephens & Co.: Overweight to Overweight | 10/10/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 10/10/2024 |
| Reiterates | Stephens & Co.: Overweight to Overweight | 9/4/2024 |
| Initiated | Leerink Partners: Outperform | 9/3/2024 |
| Maintains | UBS: Neutral to Neutral | 8/13/2024 |
Related Tickers
TEM Tempus AI, Inc
48.01
-2.12%
TDOC Teladoc Health, Inc.
9.51
-2.76%
DOCS Doximity, Inc.
42.86
-3.49%
SDGR Schr?dinger, Inc.
17.59
-1.84%
WGS GeneDx Holdings Corp.
56.00
-7.86%
VEEV Veeva Systems Inc.
217.02
-0.14%
PGNY Progyny, Inc.
16.68
+0.66%
OTRK Ontrak, Inc.
2.2800
-3.80%
ACCD Accolade, Inc.
3.5800
-4.53%
TALK Talkspace, Inc.
2.7400
-3.18%